JP Morgan Call 170 ABBV 17.05.202.../ DE000JB16CU4 /
2024-05-14 9:52:41 AM | Chg.-0.001 | Bid12:12:43 PM | Ask12:12:43 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.005EUR | -16.67% | 0.006 Bid Size: 2,000 |
0.046 Ask Size: 2,000 |
AbbVie Inc | 170.00 USD | 2024-05-17 | Call |
GlobeNewswire
9:00 AM
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
12:14 AM
In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit
GlobeNewswire
05-09
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...
GlobeNewswire
05-08
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
GlobeNewswire
05-08
Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-07
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-06
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
GlobeNewswire
05-02
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer a...
GlobeNewswire
05-01
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
04-30
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings,...
GlobeNewswire
04-30
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...
GlobeNewswire
04-25
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024